Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart
- PMID: 2038071
- DOI: 10.1016/0022-2828(91)90019-i
Amphipathic lipid metabolites and their relation to arrhythmogenesis in the ischemic heart
Abstract
Myocardial ischemia is associated with profound electrophysiologic derangements which occur within minutes and are rapidly reversible with reperfusion, suggesting that subtle and reversible biochemical alterations within or near the sarcolemma contribute. Our efforts have concentrated on two structurally similar amphipathic metabolites, long-chain acylcarnitine and lysophosphatidylcholine. Studies performed in vitro in isolated tissue indicate that incorporation of either metabolite into the sarcolemma at concentrations of 1-2 mole %, as verified using electron microscopic (EM) autoradiography, elicits profound electrophysiologic derangements analogous to those seen in the ischemic heart in vivo. In isolated myocytes in vitro, the electrophysiologic derangements elicited by hypoxia are associated with a marked 70-fold increase in the endogenous sarcolemmal accumulation of long-chain acylcarnitine. Inhibition of carnitine acyltransferase I (CAT-I) not only prevents the accumulation of long-chain acylcarnitine in isolated myocytes exposed to severe hypoxia, but also markedly attenuates the electrophysiologic alterations. Several lines of experimental evidence, including measurements in venous effluents as well as cardiac lymph, indicate that lysophosphatidylcholine (LPC) accumulates to a large extent in the extracellular space during ischemia. This extracellular accumulation may be secondary to release from vascular endothelium, smooth muscle or blood cell elements. In crude homogenates of myocardial tissue, the total enzymic activity for catabolism of LPC far exceeds the total activity for synthesis of LPC mediated by phospholipase A2 (PLA2) catalyzed hydrolysis of phosphatidylcholine (PC). Therefore, inhibition of catabolism would be required for net accumulation of LPC to occur. Three enzymes responsible for the catabolism of LPC are inhibited by either long-chain acylcarnitine or acidic pH. Thus, accumulation of long-chain acylcarnitine and acidosis contribute to the increase in LPC observed in ischemic tissue. In this report, we provide evidence that accumulation of long-chain acylcarnitine occurs very rapidly in ischemic myocardium in vivo, coincident with the development of electrophysiologic alterations leading to malignant arrhythmias as verified using 3-dimensional cardiac mapping procedures. Following a brief, 2-min period of ischemia, long-chain acylcarnitine content increased four-fold in the ischemic region, concomitant with the development of electrophysiologic abnormalities observed during this period. Additionally, we demonstrate that modification of intracellular lipolysis by beta-adrenergic receptor stimulation or blockade does not influence long-chain acylcarnitine accumulation following this 2-min interval of ischemia. These results suggest that production of long-chain acylcarnitine is not limited by the intracellular free fatty acid concentration early in ischemia.(ABSTRACT TRUNCATED AT 400 WORDS)
Similar articles
-
Selected metabolic alterations in the ischemic heart and their contributions to arrhythmogenesis.Herz. 1995 Jun;20(3):156-68. Herz. 1995. PMID: 7543431 Review.
-
Recent insights pertaining to sarcolemmal phospholipid alterations underlying arrhythmogenesis in the ischemic heart.J Cardiovasc Electrophysiol. 1993 Jun;4(3):288-310. doi: 10.1111/j.1540-8167.1993.tb01232.x. J Cardiovasc Electrophysiol. 1993. PMID: 8269301 Review.
-
Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation.J Clin Invest. 1989 Mar;83(3):927-36. doi: 10.1172/JCI113978. J Clin Invest. 1989. PMID: 2921326 Free PMC article.
-
Mechanisms contributing to the arrhythmogenic influences of alpha 1-adrenergic stimulation in the ischemic heart.Am J Med. 1989 Aug 16;87(2A):19S-25S. doi: 10.1016/0002-9343(89)90109-5. Am J Med. 1989. PMID: 2548381 Review.
-
Lysophospholipids, long chain acylcarnitines and membrane dysfunction in the ischaemic heart.Basic Res Cardiol. 1987;82 Suppl 1:199-208. doi: 10.1007/978-3-662-08390-1_24. Basic Res Cardiol. 1987. PMID: 3311006 Review.
Cited by
-
Long-Chain Acyl Carnitines Aggravate Polystyrene Nanoplastics-Induced Atherosclerosis by Upregulating MARCO.Adv Sci (Weinh). 2023 Jul;10(19):e2205876. doi: 10.1002/advs.202205876. Epub 2023 May 5. Adv Sci (Weinh). 2023. PMID: 37144527 Free PMC article.
-
Identification of three potential novel biomarkers for early diagnosis of acute ischemic stroke via plasma lipidomics.Metabolomics. 2023 Mar 30;19(4):32. doi: 10.1007/s11306-023-01990-3. Metabolomics. 2023. PMID: 36997715
-
Plasma Quantitative Lipid Profiles: Identification of CarnitineC18:1-OH, CarnitineC18:2-OH and FFA (20:1) as Novel Biomarkers for Pre-warning and Prognosis in Acute Myocardial Infarction.Front Cardiovasc Med. 2022 Apr 11;9:848840. doi: 10.3389/fcvm.2022.848840. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35479277 Free PMC article.
-
Long-Chain Acylcarnitines and Cardiac Excitation-Contraction Coupling: Links to Arrhythmias.Front Physiol. 2020 Sep 11;11:577856. doi: 10.3389/fphys.2020.577856. eCollection 2020. Front Physiol. 2020. PMID: 33041874 Free PMC article. Review.
-
Fatty acid oxidation disorders.Ann Transl Med. 2018 Dec;6(24):473. doi: 10.21037/atm.2018.10.57. Ann Transl Med. 2018. PMID: 30740404 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous